PL2201120T3 - Systemy białek fuzyjnych GCSF odpowiednie do wysokiej ekspresji peptydów - Google Patents

Systemy białek fuzyjnych GCSF odpowiednie do wysokiej ekspresji peptydów

Info

Publication number
PL2201120T3
PL2201120T3 PL08852235T PL08852235T PL2201120T3 PL 2201120 T3 PL2201120 T3 PL 2201120T3 PL 08852235 T PL08852235 T PL 08852235T PL 08852235 T PL08852235 T PL 08852235T PL 2201120 T3 PL2201120 T3 PL 2201120T3
Authority
PL
Poland
Prior art keywords
peptides
fusion protein
high expression
systems suitable
protein systems
Prior art date
Application number
PL08852235T
Other languages
English (en)
Inventor
Sanjeev Kumar Mendiretta
Pankaj R Patel
Sanjay Bandyopadhyay
Vibhor Saraswat
Arun Kumar Singh
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of PL2201120T3 publication Critical patent/PL2201120T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
PL08852235T 2007-09-21 2008-09-22 Systemy białek fuzyjnych GCSF odpowiednie do wysokiej ekspresji peptydów PL2201120T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1848MU2007 2007-09-21
EP08852235.4A EP2201120B1 (en) 2007-09-21 2008-09-22 Gcsf fusion protein systems suitable for high expression of peptides
PCT/IN2008/000599 WO2009066320A2 (en) 2007-09-21 2008-09-22 Fusion protein systems suitable for high expression of peptides

Publications (1)

Publication Number Publication Date
PL2201120T3 true PL2201120T3 (pl) 2014-05-30

Family

ID=40667943

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08852235T PL2201120T3 (pl) 2007-09-21 2008-09-22 Systemy białek fuzyjnych GCSF odpowiednie do wysokiej ekspresji peptydów

Country Status (7)

Country Link
US (1) US8507221B2 (pl)
EP (2) EP2522728A1 (pl)
JP (1) JP5368450B2 (pl)
AU (1) AU2008327513B2 (pl)
DK (1) DK2201120T3 (pl)
PL (1) PL2201120T3 (pl)
WO (1) WO2009066320A2 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2787083B1 (en) * 2009-11-09 2017-06-14 The Regents of the University of Colorado, a body corporate Efficient production of peptides
US20200009266A1 (en) * 2017-02-15 2020-01-09 Fred Hutchinson Cancer Research Center In vivo gene therapy for immune deficiencies
CN106967663B (zh) * 2017-05-06 2020-08-14 中国海洋大学 一种用于农作物病害防治的重组菌株
EP3630807A1 (en) 2017-05-25 2020-04-08 Leidos, Inc. Pd-1 and ctla-4 dual inhibitor peptides
JP2021509805A (ja) * 2017-12-27 2021-04-08 カウンシル オブ サイエンティフィック アンド インダストリアル リサーチ 顆粒球コロニー刺激因子活性を示すポリペプチド
US11267863B2 (en) 2018-01-19 2022-03-08 Pepgene Inc. N-terminal fusion partner for producing recombinant polypeptide, and method for producing recombinant polypeptide using same
JP2022533711A (ja) 2019-05-22 2022-07-25 レイドス， インコーポレイテッド Ｌａｇ３結合ペプチド
RU2728611C1 (ru) * 2019-05-24 2020-07-30 Закрытое акционерное общество "ФАРМ-ХОЛДИНГ" РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pF265, КОДИРУЮЩАЯ ГИБРИДНЫЙ ПОЛИПЕПТИД, СОДЕРЖАЩИЙ ПРОИНСУЛИН ЧЕЛОВЕКА, И ШТАММ БАКТЕРИЙ Escherichia coli - ПРОДУЦЕНТ ГИБРИДНОГО ПОЛИПЕПТИДА, СОДЕРЖАЩЕГО ПРОИНСУЛИН ЧЕЛОВЕКА
EP4188947A2 (en) 2020-07-31 2023-06-07 Leidos, Inc. Lag3 binding peptides
CN116731126B (zh) * 2023-01-30 2024-02-23 态创生物科技(广州)有限公司 内含肽ChiATP、内含肽ChiATP-二肽-2融合蛋白及二肽-2的表达方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ199391A (en) 1981-01-02 1985-12-13 Genentech Inc Chimeric polypeptides comprising a proinsulin sequence,and preparation by recombinant dna technique;production of human insulin
DE3526995A1 (de) 1985-07-27 1987-02-05 Hoechst Ag Fusionsproteine, verfahren zu ihrer herstellung und ihre verwendung
US5223404A (en) 1988-01-20 1993-06-29 Sunstar Kabushiki Kaisha Composition for testing periodontal diseases
JP3531947B2 (ja) 1991-08-19 2004-05-31 第一サントリーファーマ株式会社 ペプチドの製造方法
US5738849A (en) * 1992-11-24 1998-04-14 G. D. Searle & Co. Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them
KR100230578B1 (ko) 1997-07-25 1999-12-01 허영섭 포스포리불로키나제를 융합파트너로 이용하는 재조합 인간 부갑상선호르몬의 발현벡터
WO2007091250A2 (en) * 2006-02-06 2007-08-16 The Medical Research And Infrastructure Fund Of The Tel-Aviv Sourasky Medical Center Enzyme replacement therapy for treating lysosomal storage diseases
DK1994138T3 (da) 2006-03-06 2014-05-12 Cadila Healthcare Ltd Fremgangsmåde til fremstilling af humant g-csf

Also Published As

Publication number Publication date
WO2009066320A2 (en) 2009-05-28
AU2008327513B2 (en) 2012-05-03
WO2009066320A3 (en) 2009-09-24
AU2008327513A1 (en) 2009-05-28
EP2201120A2 (en) 2010-06-30
JP5368450B2 (ja) 2013-12-18
DK2201120T3 (en) 2014-03-17
US8507221B2 (en) 2013-08-13
EP2522728A1 (en) 2012-11-14
EP2201120B1 (en) 2013-12-25
JP2010539898A (ja) 2010-12-24
US20120142891A1 (en) 2012-06-07
AU2008327513A2 (en) 2010-06-17

Similar Documents

Publication Publication Date Title
PL2201120T3 (pl) Systemy białek fuzyjnych GCSF odpowiednie do wysokiej ekspresji peptydów
HK1219490A1 (zh) 免疫球蛋白融合蛋白
IL275846A (en) ACTRIIB–FC truncated fusion proteins
IL210175A0 (en) Fn14/trail fusion proteins
EP2161287A4 (en) OPTIMIZED TACI FC FUSION PROTEINS
IL196889A0 (en) Albumin-insulin fusion proteins
IL204839A0 (en) Albumin fusion proteins
ZA201005245B (en) Protein expression systems
EP2413969A4 (en) FUSION PROTEINS WITH DOG FC ELEMENTS
IL212538A0 (en) Albumin fusion proteins
IL197580A0 (en) Albumin fusion proteins
IL205716A0 (en) Formulations for taci-immunoglobulin fusion proteins
IL205107A0 (en) Method for purifying fc-fusion proteins
GB2465683B (en) LL-37 Related Fusion Peptides
LT2144924T (lt) Sulieto baltymo vakcina
GB0725201D0 (en) Peptide fusion proteins
IL205718A0 (en) Taci-immunoglobulin fusion proteins for treatment of relapsing multiple sclerosis
GB0813253D0 (en) Protein expression system
GB0700759D0 (en) Novel fusion protein
GB0713169D0 (en) Fusion proteins
GB0709707D0 (en) Novel fusion protein
GB0919753D0 (en) Interferon lambda fusion proteins
AU2007901829A0 (en) Method of purifying peptides
GB0715325D0 (en) Fertilisation protein
GB0922155D0 (en) Interferon 8 fusion proteins